DXCM vs. LLY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at DXCM and LLY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | DXCM | LLY |
|---|---|---|
| Company Name | DexCom, Inc. | Eli Lilly and Company |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 31.36 billion USD | 592.10 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | April 14, 2005 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of DXCM and LLY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | DXCM | LLY |
|---|---|---|
| 5-Day Price Return | 4.66% | 3.06% |
| 13-Week Price Return | -5.98% | -12.58% |
| 26-Week Price Return | -9.47% | -24.11% |
| 52-Week Price Return | 12.19% | -25.32% |
| Month-to-Date Return | -1.00% | -10.75% |
| Year-to-Date Return | 2.82% | -14.44% |
| 10-Day Avg. Volume | 5.06M | 8.71M |
| 3-Month Avg. Volume | 3.92M | 4.45M |
| 3-Month Volatility | 36.35% | 41.63% |
| Beta | 1.49 | 0.45 |
Profitability
Return on Equity (TTM)
DXCM
25.62%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
In the upper quartile for the Health Care Equipment & Supplies industry, DXCM’s Return on Equity of 25.62% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
LLY
88.36%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
DXCM
13.29%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
A Net Profit Margin of 13.29% places DXCM in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.
LLY
25.91%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
DXCM
15.98%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
DXCM’s Operating Profit Margin of 15.98% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
LLY
32.37%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | DXCM | LLY |
|---|---|---|
| Return on Equity (TTM) | 25.62% | 88.36% |
| Return on Assets (TTM) | 8.49% | 16.02% |
| Net Profit Margin (TTM) | 13.29% | 25.91% |
| Operating Profit Margin (TTM) | 15.98% | 32.37% |
| Gross Profit Margin (TTM) | 60.01% | 82.64% |
Financial Strength
Current Ratio (MRQ)
DXCM
1.52
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
DXCM’s Current Ratio of 1.52 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
LLY
1.28
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
DXCM
0.97
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
DXCM’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.97. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
LLY
2.18
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
DXCM
978.00
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
With an Interest Coverage Ratio of 978.00, DXCM demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.
LLY
20.36
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | DXCM | LLY |
|---|---|---|
| Current Ratio (MRQ) | 1.52 | 1.28 |
| Quick Ratio (MRQ) | 1.32 | 0.53 |
| Debt-to-Equity Ratio (MRQ) | 0.97 | 2.18 |
| Interest Coverage Ratio (TTM) | 978.00 | 20.36 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
DXCM
0.00%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
DXCM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
LLY
0.82%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
LLY’s Dividend Yield of 0.82% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
DXCM
0.00%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
DXCM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
LLY
36.46%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | DXCM | LLY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.82% |
| Dividend Payout Ratio (TTM) | 0.00% | 36.46% |
Valuation
Price-to-Earnings Ratio (TTM)
DXCM
55.47
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
A P/E Ratio of 55.47 places DXCM in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
LLY
44.55
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 44.55, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
DXCM
7.37
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
DXCM’s P/S Ratio of 7.37 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
LLY
11.54
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
With a P/S Ratio of 11.54, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
DXCM
13.30
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
At 13.30, DXCM’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
LLY
40.43
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | DXCM | LLY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 55.47 | 44.55 |
| Price-to-Sales Ratio (TTM) | 7.37 | 11.54 |
| Price-to-Book Ratio (MRQ) | 13.30 | 40.43 |
| Price-to-Free Cash Flow Ratio (TTM) | 55.54 | 305.94 |